Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | -4.47%3B | -4.70%2.01B | -5.71%1.02B | -1.99%4.18B | -1.32%3.14B | 0.02%2.11B | 2.60%1.08B | 17.63%4.27B | 17.34%3.18B | 19.60%2.11B |
| Cash received relating to other operating activities | -39.23%29.53M | -55.00%20.29M | -17.61%10.15M | 45.90%55.61M | 33.50%48.6M | 115.78%45.09M | -4.07%12.32M | -81.24%38.12M | -81.53%36.4M | -68.63%20.9M |
| Cash inflows from operating activities | -5.00%3.03B | -5.75%2.03B | -5.85%1.03B | -1.57%4.24B | -0.93%3.19B | 1.15%2.15B | 2.52%1.09B | 12.39%4.3B | 10.64%3.22B | 16.39%2.13B |
| Goods services cash paid | -1.62%476.78M | -6.60%299.04M | -2.62%148.62M | 3.74%688.18M | 11.34%484.62M | 13.20%320.16M | 8.23%152.63M | 24.32%663.39M | 22.10%435.27M | 34.05%282.84M |
| Staff behalf paid | 1.33%394.8M | 1.43%293.68M | 1.14%191.7M | 5.77%489.93M | 6.21%389.63M | 8.84%289.54M | 13.63%189.54M | 5.51%463.22M | 6.59%366.84M | 5.23%266.04M |
| All taxes paid | -5.81%608.36M | -5.58%460.46M | -7.94%135M | 1.24%978.44M | 3.52%645.87M | 4.47%487.67M | 14.84%146.65M | 18.46%966.45M | 29.29%623.89M | 27.18%466.82M |
| Cash paid relating to other operating activities | 9.77%191.14M | 17.63%134.43M | 1.50%63.63M | -2.98%283.52M | -5.45%174.13M | -5.68%114.28M | -12.29%62.69M | 34.80%292.24M | 21.39%184.16M | 32.42%121.16M |
| Cash outflows from operating activities | -1.37%1.67B | -1.99%1.19B | -2.28%538.96M | 2.30%2.44B | 5.22%1.69B | 6.58%1.21B | 8.78%551.51M | 18.95%2.39B | 20.62%1.61B | 23.26%1.14B |
| Net cash flows from operating activities | -9.12%1.36B | -10.59%842.59M | -9.48%489.66M | -6.38%1.8B | -7.09%1.49B | -5.06%942.42M | -3.17%540.96M | 5.17%1.92B | 2.17%1.61B | 9.41%992.64M |
| Investing cash flow | ||||||||||
| Cash received from returns on investments | ---- | ---- | ---- | 603.33%6.33M | 603.33%6.33M | 553.33%5.88M | --5.88M | --900K | --900K | --900K |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | -61.67%95.74K | -94.60%11.32K | -85.00%1.8K | 12.87%311.92K | 0.32%249.77K | 7.54%209.61K | 65.40%11.97K | 120.35%276.34K | 100.17%248.98K | 196.63%194.91K |
| Cash inflows from investing activities | -98.54%95.74K | -99.81%11.32K | -99.97%1.8K | 464.63%6.64M | 472.66%6.58M | 456.17%6.09M | 81,292.08%5.89M | 838.02%1.18M | 823.76%1.15M | 1,566.33%1.09M |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | 10.16%50.16M | 9.50%31.1M | 22.88%14.75M | 3.44%68.28M | 3.36%45.53M | -4.79%28.4M | -16.33%12M | -6.15%66.01M | 4.81%44.05M | -1.58%29.83M |
| Cash paid to acquire investments | ---- | ---- | ---- | --2M | --2M | --2M | ---- | ---- | ---- | ---- |
| Cash outflows from investing activities | 5.52%50.16M | 2.29%31.1M | 22.88%14.75M | 6.47%70.28M | 7.90%47.53M | 1.92%30.4M | -16.33%12M | -6.15%66.01M | 4.81%44.05M | -1.58%29.83M |
| Net cash flows from investing activities | -22.24%-50.06M | -27.87%-31.09M | -141.32%-14.75M | 1.85%-63.64M | 4.55%-40.95M | 15.39%-24.31M | 57.38%-6.11M | 7.66%-64.84M | -2.38%-42.9M | 4.99%-28.73M |
| Financing cash flow | ||||||||||
| Borrowing repayment | 39.80%685M | 1,070.00%585M | ---- | -3.92%490M | -2.00%490M | --50M | --50M | -8.93%510M | -10.71%500M | ---- |
| Dividend interest payment | -16.72%1.13B | -15.57%1.12B | -11.74%9.63M | 76.00%1.36B | 77.32%1.35B | 80.29%1.33B | -33.68%10.91M | 10.64%775.15M | 11.68%763.86M | 13.98%738.36M |
| -Including:Cash payments for dividends or profit to minority shareholders | --250K | --250K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash payments relating to other financing activities | 10.30%1.63M | 3.17%1.24M | 0.00%277.82K | 0.00%4.68M | 0.00%1.48M | 0.00%1.2M | 0.00%277.82K | 0.00%4.68M | 0.00%1.48M | 0.00%1.2M |
| Cash outflows from financing activities | -1.70%1.81B | 23.71%1.71B | -83.81%9.91M | 44.12%1.86B | 45.89%1.85B | 86.92%1.38B | 265.79%61.19M | 1.94%1.29B | 1.60%1.27B | -35.63%739.57M |
| Net cash flows from financing activities | 1.70%-1.81B | -23.71%-1.71B | 83.81%-9.91M | -44.12%-1.86B | -45.89%-1.85B | -86.92%-1.38B | -265.79%-61.19M | -1.94%-1.29B | -1.60%-1.27B | 35.63%-739.57M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | -1,736.88%-20.77K | -2,575.29%-40.97K | -260.04%-10.01K | 94.15%-21.91K | 100.34%1.27K | 100.41%1.66K | 102.26%6.26K | -874.73%-374.55K | -39.16%-372.32K | -221.90%-405.14K |
| Net increase in cash and cash equivalents | -29.07%-506.48M | -93.56%-898.67M | -1.83%464.99M | -122.41%-126.3M | -230.81%-392.39M | -307.33%-464.28M | -10.17%473.67M | 15.29%563.62M | 4.61%299.97M | 182.29%223.93M |
| Add:Begin period cash and cash equivalents | -3.25%3.76B | -3.25%3.76B | -3.25%3.76B | 16.94%3.89B | 16.94%3.89B | 16.94%3.89B | 16.94%3.89B | 17.23%3.33B | 17.23%3.33B | 17.23%3.33B |
| End period cash equivalent | -6.87%3.26B | -16.37%2.87B | -3.09%4.23B | -3.25%3.76B | -3.55%3.5B | -3.51%3.43B | 13.23%4.36B | 16.94%3.89B | 16.07%3.63B | 38.39%3.55B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Deloitte Huayong Certified Public Accountants (Special General Partnership) | -- | -- | -- | PricewaterhouseCoopers Zhongtian Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.